Related Experiment Video
Updated: May 15, 2025
Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil
Published on: October 4, 2016
Posttraumatic Headache: A Possible Therapeutic Target of Transcranial Magnetic Stimulation
Anika Balse1, Christine N Smith1, William Drew1
1Kaizen Brain Center, La Jolla, Calif. (Balse, Ansari, Chaudry, Karanam, Ahmed); Veterans Affairs San Diego Healthcare System, San Diego (Smith, Golshan); Departments of Psychiatry (Smith, Golshan) and Neurosciences (Ansari), University of California San Diego, La Jolla; Brigham and Women's Hospital, Harvard University, Cambridge, Mass. (Drew).
Objective:
Persistent headache is the most common and debilitating chronic condition after traumatic brain injury (TBI), affecting mood and reducing quality of life. The investigators examined in a community-based setting whether repetitive transcranial magnetic stimulation (rTMS) for management of major depression among outpatients with TBI histories was associated with improvement in the functional impact of headache (FH) and whether improvements were related to treatment at a specific site in the dorsolateral prefrontal cortex (DLPFC).
Methods:
In the discovery phase (posttraumatic headache 1 [PTH-1] group, N=21), the association of rTMS treatment at DLPFC targets and improvement in headache and depression and anxiety were studied. Associations between functional connectivity of the patient-specific TMS treatment sites and changes in patients' FH were used to identify a target for simultaneous treatment of behavioral and headache symptoms. Patients in the translational phase (PTH-2 group, N=7) received TMS treatment at this target.
Results:
The patients in the PTH-1 group had significant improvements in depression and anxiety but not FH, and more than half had a reduction in FH and reported an improvement in headache severity and duration. Increased functional connectivity between TMS sites and a subregion in the left DLPFC and bilateral precuneus was related to improved FH. Unlike the PTH-1 group, the PTH-2 group exhibited significant reductions in FH after 4 weeks of treatment and in anxiety and depression after 1-2 weeks of treatment.
Conclusions:
TMS treatment targeting the left DLPFC coordinate identified in this study may help improve treatment for both FH and anxiety and depression among PTH patients.
